Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between ...

Alameda’s Penumbra, Inc., a medical device company founded by Arani Bose and Adam Elsesser in 2004, has agreed to be acquired ...

Penumbra’s stock was up about 12% after the deal was announced Thursday morning.

Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...

Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...

Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a ...

BOSTON--(BUSINESS WIRE)--Penumbra, Inc. (NYSE:PEN), a global interventional therapies company, today announced U.S. commercial availability of its most advanced thrombectomy device, the ACE™68 ...

Now available in the U.S., RED™ 62 is engineered with optimized trackability to help navigate the complex distal vessel anatomy in the brain and deliver powerful aspiration for the removal of blood ...

Boston Scientific said it will pay $374 a share in cash and stock for Penumbra, which makes products to remove blood clots ...

ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc (PEN). (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for ...

The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion. Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, ...

Boston Scientific (NYSE:BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker ...